DE60144514D1 - Verwendung von il-18 inhibitoren - Google Patents

Verwendung von il-18 inhibitoren

Info

Publication number
DE60144514D1
DE60144514D1 DE60144514T DE60144514T DE60144514D1 DE 60144514 D1 DE60144514 D1 DE 60144514D1 DE 60144514 T DE60144514 T DE 60144514T DE 60144514 T DE60144514 T DE 60144514T DE 60144514 D1 DE60144514 D1 DE 60144514D1
Authority
DE
Germany
Prior art keywords
inhibitors
medicament
prevention
preparation
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60144514T
Other languages
English (en)
Inventor
Yolande Chvatchko
Charles Dinarello
Christine Plater-Zyberk
DEVENTER Santer VAN
Menachem Rubinstein
Daniela Novick
Soo-Hyun Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Yeda Research and Development Co Ltd
Original Assignee
Merck Serono SA
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono SA, Yeda Research and Development Co Ltd filed Critical Merck Serono SA
Application granted granted Critical
Publication of DE60144514D1 publication Critical patent/DE60144514D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60144514T 2000-02-21 2001-02-20 Verwendung von il-18 inhibitoren Expired - Lifetime DE60144514D1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP00103597 2000-02-21
EP00103590 2000-02-21
EP00121651 2000-10-04
EP00125633 2000-11-23
PCT/EP2001/001867 WO2001062285A1 (en) 2000-02-21 2001-02-20 Use of il-18 inhibitors

Publications (1)

Publication Number Publication Date
DE60144514D1 true DE60144514D1 (de) 2011-06-09

Family

ID=27439934

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60144514T Expired - Lifetime DE60144514D1 (de) 2000-02-21 2001-02-20 Verwendung von il-18 inhibitoren

Country Status (31)

Country Link
US (1) US20030157094A1 (de)
EP (1) EP1257292B1 (de)
JP (1) JP4744763B2 (de)
KR (3) KR20070087256A (de)
CN (1) CN1322897C (de)
AT (1) ATE506959T1 (de)
AU (2) AU4063601A (de)
BG (1) BG66134B1 (de)
BR (1) BR0108514A (de)
CA (2) CA2683009C (de)
CY (1) CY1111687T1 (de)
CZ (1) CZ304485B6 (de)
DE (1) DE60144514D1 (de)
DK (1) DK1257292T3 (de)
EA (1) EA005583B1 (de)
EE (1) EE05423B1 (de)
HK (1) HK1051965A1 (de)
HR (1) HRP20020652A2 (de)
HU (1) HU227752B1 (de)
IL (2) IL151388A0 (de)
ME (1) ME00546B (de)
MX (1) MXPA02008079A (de)
NO (1) NO331971B1 (de)
NZ (3) NZ546294A (de)
PL (1) PL206549B1 (de)
PT (1) PT1257292E (de)
RS (1) RS51737B (de)
SI (1) SI1257292T1 (de)
SK (1) SK288032B6 (de)
TR (2) TR200502508T2 (de)
WO (1) WO2001062285A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ520392A (en) * 2000-02-10 2005-04-29 Abbott Lab Antibodies that bind human interleukin-18 and methods of making and using
ME00546B (me) * 2000-02-21 2011-10-10 Serono Lab Korišćenje inhibitora il-18
EP2357002A1 (de) 2000-10-11 2011-08-17 Viron Therapeutics, Inc. Nukleinsäuremoleküle und Polypeptide zur Immunmodulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
US20030008822A1 (en) * 2001-05-16 2003-01-09 Charles Dinarello Use of IL-18 inhibitors for the treatment or prevention of sepsis
JP2005510542A (ja) * 2001-11-30 2005-04-21 ファイザー・プロダクツ・インク 炎症の治療のための、ｉｌ−１／１８阻害剤及びｔｎｆ阻害剤の組み合わせ。
WO2004064713A2 (en) * 2003-01-20 2004-08-05 Vib Vzw The use of yop preoteins or rho gtpase inhibitors as caspase-1 inhibitors
EP1621616A4 (de) 2003-04-30 2007-07-04 Japan Science & Tech Agency Menschlicher anti-mensch-interleukin-18-antikörper, fragment davon und verfahren zu deren verwendung
CA2545733A1 (en) * 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methods for monitoring il-18
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
DK2177907T3 (da) 2004-06-30 2014-03-24 Atsuo Sekiyama Indikatormiddel til ikke-inflammatorisk stressreaktion og anvendelse dertil
JP5595632B2 (ja) * 2004-07-16 2014-09-24 敦生 関山 Ｉｌ−１８レセプターアンタゴニスト、および当該アンタゴニストを含む薬学的組成物
ATE557038T1 (de) 2005-06-03 2012-05-15 Ares Trading Sa Herstellung von rekombinantem il-18 bindendem protein
EP1891088B1 (de) 2005-06-10 2011-10-19 Ares Trading S.A. Verfahren zur reinigung eines il-18-bindenden proteins
EP1746167A1 (de) * 2005-07-20 2007-01-24 Apoxis SA Verfahren zur Identifizierung von Verbindungen, welche Entzündung inhibieren können.
KR101416078B1 (ko) 2006-05-25 2014-07-07 글락소 그룹 리미티드 변형된 인간화 항­인터루킨­１８ 항체
US8440195B2 (en) * 2010-11-12 2013-05-14 National University Corporation Chiba University Inhibition of CD69 for treatment of inflammatory conditions
GB201213968D0 (en) * 2012-08-06 2012-09-19 Isis Innovation Prevention and treatment of osteoarthritis
EP3041864B1 (de) * 2013-09-05 2021-07-21 AB2 Bio SA Il-18-bindendes protein (il-18bp) bei entzündungskrankheiten
AU2016227644B2 (en) * 2015-03-05 2022-06-16 Ab2 Bio Sa IL-18 Binding Protein (IL-18BP) and antibodies in inflammatory diseases
CN106109497A (zh) * 2016-07-25 2016-11-16 深圳爱生再生医学科技有限公司 治疗肝硬化的干细胞制剂
CN106834449B (zh) * 2017-01-10 2019-04-30 东南大学 与原发性胆汁性胆管炎关联的白细胞介素21受体及其应用
WO2019238893A1 (en) * 2018-06-14 2019-12-19 Universite de Bordeaux Treatment of placental chronic histiocytic intervillositis using an inhibitor of interleukin-1
JPWO2023286694A1 (de) 2021-07-13 2023-01-19
CN117647645B (zh) * 2024-01-29 2024-04-12 中国人民解放军总医院第一医学中心 Lbp、atf6、m-csfr联用在制备诊断自身免疫性肝病产品中的应用及试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
DE69726878T2 (de) * 1996-11-15 2004-10-21 Kennedy Inst Of Rheumatology L UNTERDRÜCKUNG VON TNFalpha UND IL-12 IN DER THERAPIE
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
JP4026923B2 (ja) * 1997-03-12 2007-12-26 株式会社林原生物化学研究所 ポリペプチド
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
NZ520392A (en) * 2000-02-10 2005-04-29 Abbott Lab Antibodies that bind human interleukin-18 and methods of making and using
ME00546B (me) * 2000-02-21 2011-10-10 Serono Lab Korišćenje inhibitora il-18
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
JP2003523403A (ja) 2003-08-05
MXPA02008079A (es) 2003-02-27
NO331971B1 (no) 2012-05-14
HU227752B1 (en) 2012-02-28
TR200202030T2 (tr) 2003-01-21
CA2399298A1 (en) 2001-08-30
HK1051965A1 (en) 2003-08-29
BG107018A (bg) 2003-09-30
KR20070057282A (ko) 2007-06-04
NO20023962D0 (no) 2002-08-20
US20030157094A1 (en) 2003-08-21
CZ20022843A3 (cs) 2003-02-12
CN1404400A (zh) 2003-03-19
RS51737B (sr) 2011-10-31
CN1322897C (zh) 2007-06-27
IL151388A (en) 2009-09-01
BR0108514A (pt) 2002-12-17
TR200502508T2 (tr) 2007-04-24
NO20023962L (no) 2002-08-20
AU2001240636B2 (en) 2005-10-13
AU4063601A (en) 2001-09-03
CY1111687T1 (el) 2015-10-07
DK1257292T3 (da) 2011-07-18
KR20070087256A (ko) 2007-08-27
PT1257292E (pt) 2011-07-05
ATE506959T1 (de) 2011-05-15
CA2683009C (en) 2014-09-23
NZ535299A (en) 2006-06-30
HUP0300061A3 (en) 2005-09-28
EP1257292B1 (de) 2011-04-27
YU60402A (sh) 2005-09-19
CZ304485B6 (cs) 2014-05-28
IL151388A0 (en) 2003-04-10
NZ546294A (en) 2008-02-29
EA005583B1 (ru) 2005-04-28
SI1257292T1 (sl) 2011-08-31
EE05423B1 (et) 2011-06-15
BG66134B1 (bg) 2011-06-30
ME00546B (me) 2011-10-10
PL206549B1 (pl) 2010-08-31
SK288032B6 (sk) 2012-12-03
WO2001062285A1 (en) 2001-08-30
HRP20020652A2 (en) 2004-12-31
CA2399298C (en) 2014-04-15
EP1257292A1 (de) 2002-11-20
JP4744763B2 (ja) 2011-08-10
PL357554A1 (en) 2004-07-26
EE200200463A (et) 2003-12-15
CA2683009A1 (en) 2001-08-30
AU2001240636B8 (en) 2005-11-03
NZ520122A (en) 2005-04-29
HUP0300061A2 (hu) 2003-04-28
SK12082002A3 (sk) 2003-05-02
EA200200890A1 (ru) 2003-02-27
KR20020086540A (ko) 2002-11-18

Similar Documents

Publication Publication Date Title
DE60144514D1 (de) Verwendung von il-18 inhibitoren
GB0223040D0 (en) Therapeutic compounds
GB0025173D0 (en) Therapeutic agents
EP1769791A3 (de) Therapeutische strategien für die prävention und behandlung der alzeheimer-krankheit
ATE510562T1 (de) Anti-ailim antikörper zur behandlung von crohn's
GB0005251D0 (en) Therapeutic compounds
HRP20130602T1 (en) 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
WO2004006858A3 (en) Compounds, compositions, and methods employing same
MA27374A1 (fr) Ester de 2'-c-methyl-3'-o-l-valine et de ribofuranosyl cytidine pour le traitement des infections des flaviviridae
EP1562897A4 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
ATE232396T1 (de) Oxydiertes thymosin beta 4
WO2001035950A3 (en) Benzamide therapeutics and methods for treating inflammatory bowel disease
CY1114133T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ γ-ΦΑΙΝΥΛ-Δ-ΛΑΚΤΑΜΕΣ ΚΑΙ ΧΡΗΣΕΙΣ ΠΟΥ ΣΧΕΤΙΖΟΝΤΑΙ ΠΡΟΣ ΑΥΤΕΣ
ATE282411T1 (de) Eisenverbindungen
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
ATE423102T1 (de) 4-substituirte-5-cyano-1h-pyrimidin-6-(th)iones als als gsk-3-hemmer
NO20032597D0 (no) Anvendelse av SARP-1 for behandlingen og/eller forebyggingen av skleroderma
NO20020369L (no) Sammensetninger for forebyggelse og behandling av nyredysfunksjoner og -sykdommer
BRPI0417146A (pt) combinações farmacêuticas
TR200502061T2 (tr) IL-18 inhibitörlerinin kullanımı.
DE60126504D1 (de) Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa
SI1656372T1 (sl) Spojine 2,4-pirimidindiamina za uporabo pri zdravljenju ali preventivi avtoimunih bolezni